| Document |
Document Title |
|
WO/2023/031959A1 |
The present invention relates to a process for preparation of a substantially colour-free Bixafen which comprises treating the crude bixafen with an organic solvent.
|
|
WO/2023/016447A1 |
This disclosure provides compounds of Formula I, compositions comprising the same, and methods of using the same, including use in treating various diseases and conditions, e.g., those involving ferroptosis.
|
|
WO/2023/012643A1 |
The present invention relates to an industrial process for the preparation of 3-bromo-1-(3-chloropyridin-2-yl)-1H-pyrazol-5-carboxylic acid of formula (I). The present invention further involves the preparation of 3-bromo-1-(3-chloropyri...
|
|
WO/2023/014793A1 |
The disclosure relates to synthetic methods for producing polyamides, for example pyrrole and imidazole containing polyamides of Formula (I) or (II), or a pharmaceutically acceptable salts thereof. These polyamides bind genes having expa...
|
|
WO/2023/009612A1 |
Provided herein are acoramidis (3-(3-(3,5-dimethyl-lH-pyrazol-4-yl) propoxy)-4-fluorobenzoic acid) derivatives of formula (I) wherein A is having activity against transthyretin (TTR) related conditions. Also provided are the compounds fo...
|
|
WO/2023/004280A1 |
Compounds and methods are provided for the treatment of leucine-rich repeat kinase-2 (LRRK2)-related diseases associated with increased LRRK2 kinase activity, including but not limited to neurodegeneration, inflammatory bowel disease, an...
|
|
WO/2023/283831A1 |
Disclosed in the present invention is a compound having an inhibitory effect on a virus main protease (3CL protease, Mpro), which also has a significant inhibitory activity on the Mpros of SARS coronavirus (SARS-CoV) and novel coronaviru...
|
|
WO/2023/284775A1 |
Provided are a pyrazole derivative, and an intermediate thereof and a preparation method therefor. The method has the characteristics of a simple operation, high selectivity, low cost, environmental friendliness, etc., and is suitable fo...
|
|
WO/2023/283743A1 |
The present invention provides compounds of formula (I): NR1R2SOOYR3 (I) or a pharmaceutically acceptable salt thereof. The present invention also provides pharmaceutical compositions comprising a compound of formula (I), and use of the ...
|
|
WO/2023/285787A1 |
A process for preparing a compound of formula I, or a salt thereof, as defined herein. Also, compounds of formula I and intermediate compounds useful in the preparation of a compound of formula I.
|
|
WO/2023/284765A1 |
A substituted pyrazole compound, a composition containing the compound, and a use thereof, the compound being a compound represented by formula (I) or a tautomer, stereoisomer, prodrug, crystal form, pharmaceutically acceptable salt, hyd...
|
|
WO/2023/284761A1 |
The present invention relates to a pyrazole ether compound, and a preparation method therefor and the use thereof. The compound has a structure as represented by formula I, has a significant effect on the prevention and control of diseas...
|
|
WO/2023/285788A1 |
A process for preparing a compound of formula (I), or a salt thereof, as defined herein. Also, compounds of formula I and intermediate compounds useful in the preparation of a compound of formula (I).
|
|
WO/2023/280630A1 |
The present invention relates to a process for the preparation of substituted amidoximes of formula I, which can be obtained through reaction of nitrile compounds of formula II with free hydroxylamine in the presence of a solvent.
|
|
WO/2023/282110A1 |
A nematocidal composition is provided that exhibits excellent nematocidal properties. This invention relates to a nematocidal composition that contains, as an effective component, a compound represented in formula (I) or a salt thereof...
|
|
WO/2023/283453A1 |
The disclosure herein provides phenyl acetamide based compounds of Formula (I), (I-a), (II), and pharmaceutical compositions thereof, for the modulation of IL-17A, useful in the treatment of inflammatory conditions such as psoriasis.
|
|
WO/2023/279671A1 |
Provided in the present invention is a method for synthesizing 5-amino-3-cyano-1-(2,6-dichloro-4-trifluoromethyl-phenyl)pyr
azole disulfide (III), which belongs to the field of pharmaceutical synthesis. The method comprises: (1) allowing...
|
|
WO/2023/280254A1 |
Provided are a compound as shown in formula (I), a tautomer, a stereoisomer, a hydrate, a solvate, a pharmaceutically acceptable salt or a prodrug thereof. The definition of each group in formula (I) is as described in the present invent...
|
|
WO/2023/280765A1 |
The present invention relates to the choline salt (cholinate) of 2-(1-cyclobutyl-1H- pyrazol-4-yl)-5-[([1-[2-fluoro-4-(trifluoromethyl)- phenyl]cyclopropyl}carbonyl)amino]benzoic acid. In particular, the invention relates to the compound...
|
|
WO/2023/281505A1 |
The invention provides compounds and uses thereof in the treatment and prevention of diseases and conditions associate with or aggravated by impaired mitophagy or oxidative stress, and methods of their preparation.
|
|
WO/2023/275796A1 |
The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combina...
|
|
WO/2023/277517A1 |
The present invention relates to a compound represented by chemical formula 1 or a pharmaceutically acceptable salt thereof, which, by inhibiting the replication of an RNA virus by being integrated as a nucleotide derivative into a polym...
|
|
WO/2022/268080A1 |
The present application relates to a TRK kinase inhibitor compound and a use thereof. Specifically, the present application discloses a compound as shown in formula (I), an isotopically labeled compound thereof, an optical isomer, a geom...
|
|
WO/2022/269049A1 |
Provided herein are compounds of Formula (I), or pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, A, L1, L2, Y and Z are defined herein. Also provided herein are pharmaceutical compositions comprising a compound of Formu...
|
|
WO/2022/268933A1 |
The present invention relates to novel herbicidally effective (1,4,5-trisubstituted-1H-pyrazole-3-yl)oxy-2-alkoxy alkyl acids and their derivatives according to general formula (I) and their agrochemically compatible/acceptable salts, N-...
|
|
WO/2022/263829A1 |
The invention relates to compounds or salts of Formula (I-a), Formula (I-b), Formula (I-c), Formula (I-d), Formula (II) and pharmaceutical compositions containing these compounds. The compounds may be inducers of α1-antitrypsin (A1AT), ...
|
|
WO/2022/266357A1 |
The present invention relates to a combination comprising a neurotensin receptor binding compound and NAPOX for use for the treatment of a neurotensin receptor overexpressing tumour in a subject.
|
|
WO/2022/263498A1 |
The present invention relates to compounds according to general formula (I) which act as inhibitors of NaV1.8 and can be used in the treatment of pain.
|
|
WO/2022/266368A1 |
Disclosed herein are compounds that inhibit the 3C-like protease of SARS-CoV-2. Also disclosed herein are pharmaceutical compositions comprising the compounds, and methods of using the compounds, e.g., in a method of treating a viral inf...
|
|
WO/2022/262657A1 |
The present invention relates to an N-substituted phenylsulfonamide compound and a use thereof. Specifically, the present invention provides a compound represented by formula I, or an optical isomer thereof, or a racemate thereof, or a p...
|
|
WO/2022/257960A1 |
A bicyclic compound represented by formula I, and tautomers, stereoisomers, hydrates, solvates, pharmaceutically acceptable salts, or prodrugs thereof; the bicyclic compound can be used for the treatment of EP2 and EP4 receptor-mediated ...
|
|
WO/2022/258792A1 |
The present invention relates to new cinnamic add amides which may be used for treatment of fibrosis and neoplasia and to cinnamic acid amides for use in the treatment of fibrosis, neoplasia, arthrolithiasis, familiar mediterranean fever...
|
|
WO/2022/257598A1 |
The present invention belongs to the technical field of organic intermediate synthesis, and provides a method for the light-promoted oxidation of a compound containing a saturated carbon-hydrogen bond, comprising: mixing a compound conta...
|
|
WO/2022/257961A1 |
A benzoheterocyclic compound as represented by formula (I), a tautomer, a stereoisomer, a hydrate, a solvate, a pharmaceutically acceptable salt or a prodrug thereof for treating EP2 and EP4 receptor-mediated diseases, which can be used ...
|
|
WO/2022/261220A1 |
Proteolysis-targeting chimeras (PROTACs) that indirectly inhibit Myeloid Cell Leukemia- 1 (Mcl-1) oncoprotein, and methods of using the same, are provided for treating disease.
|
|
WO/2022/253645A1 |
A compound of formula (I) wherein the substituents are as defined in claim 1, and the agrochemically acceptable salts, stereoisomers, enantiomers, tautomers and N-oxides of those compounds, which can be used as fungicides.
|
|
WO/2022/256358A1 |
The present application affords an improved preparation of 3-(5-chloro-2-(difluoromethoxy)phenyl)-1H-pyrazol-4-amine hydrochloride qhich was a useful intermediate in the synthesis of JAK inhibitors.
|
|
WO/2022/255499A1 |
The purpose of the present invention is to provide a novel AMP-activated protein kinase activator. The present invention relates to a compound represented by formula (I): [wherein each symbol is as defined in the description], or a salt ...
|
|
WO/2022/256075A1 |
Pyrimidine and Pyridine amine containing compounds are described herein that are enzyme p70S6K inhibitors useful in the treatment of S6K-dependent or S6K-mediated diseases and conditions, including but not limited to cancer, fibrotic met...
|
|
WO/2022/253328A1 |
An HPK1 kinase inhibitor, and a preparation method therefor and an application thereof. Specifically, a compound shown in formula (I), the compound having HPK1 inhibitory activity and being used for preparing a pharmaceutical composition...
|
|
WO/2022/251533A1 |
Provided herein are compounds that activate IRE1/XBP1s, and pharmaceutically acceptable derivatives thereof. Also provided are pharmaceutical compositions containing the compounds and methods of using the compounds for treating a subject...
|
|
WO/2022/247862A1 |
The present invention relates to a benzospiroheterocyclic derivative of formula (II) and a pharmaceutically acceptable salt thereof.
|
|
WO/2022/249203A1 |
The present invention relates to a novel a compound of formula (I) or its salt. The present invention further relates to process for preparation of Pyroxasulfone using said compound of formula (I) or its salt.
|
|
WO/2022/242581A1 |
Provided herein are compounds of Formula Ia and Ib, compositions comprising the same, and methods of using the same, including use in treating various diseases and conditions, including those mediated by receptor-interacting protein 1 (R...
|
|
WO/2022/245627A1 |
In one aspect, the application relates to sulfonyl chalcogenide urea derivatives of Formula II, including sulfonyl thioureas and sulfonyl selenoureas, and methods of making the same, wherein the methods can be carried out under mild cond...
|
|
WO/2022/243523A1 |
The present invention relates to novel nitrification inhibitors of formula I, which are N- functionalized alkoxy pyrazole compounds. Moreover, the invention relates to the use of compounds of formula I as nitrification inhibitors, i.e. f...
|
|
WO/2022/243097A1 |
A process to produce N-vinyl compounds by homogeneous catalysis, wherein acetylene is re-acted with a compound having at least one nitrogen bearing a substitutable hydrogen residue in a liquid phase in the presence of at least one phosph...
|
|
WO/2022/238707A1 |
The present invention relates to a group of resorcinol derivatives as a pharmaceutically active compounds and methods of preparation thereof. Resorcinol derivatives have been used to treat various diseases and disorders. While such treat...
|
|
WO/2022/237903A1 |
Provided are a quinazoline compound and an application thereof. Specifically provided is a quinazoline compound as shown in formula I. The compound is novel in structure and has a good inhibitory effect on cell factors TNF-α, IL-6, and ...
|
|
WO/2022/240277A1 |
The invention relates to novel compounds of formulae (I) and (II), to the use thereof as a drug, particularly for the treatment of SARS-CoV-2, for the treatment of COVID-19 disease and any diseases related to beta-coronaviruses, and for ...
|
